Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

What's New in TIND?

Julian Marcon1, Giuseppe Magistro1, Christian G Stief1

  • 1Department of Urology, Ludwig-Maximilian University of Munich, Munich, Germany.

European Urology Focus
|April 30, 2018
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterization of Human Papilloma Virus in Prostate Cancer Patients Undergoing Radical Prostatectomy-A Prospective Study of 140 Patients.

Viruses·2023
Same author

Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003.

Frontiers in pharmacology·2023
Same author

Methylation status of various gene loci in localized prostate cancer: Novel biomarkers for diagnostics and biochemical recurrence.

Urologic oncology·2023
Same author

[Current state of prostate biopsy].

Urologie (Heidelberg, Germany)·2023
Same author

[Early detection of prostate cancer].

MMW Fortschritte der Medizin·2023
Same author

[Urinary tract infections in children].

MMW Fortschritte der Medizin·2023
Same journal

Should Male Pattern Baldness Be Considered in Prostate Cancer Risk Assessment? A Systematic Review and Meta-analysis.

European urology focus·2026
Same journal

A Core Outcome Set for Localized Renal Cell Cancer (L-RCC-COS).

European urology focus·2026
Same journal

Reply to Emre Karabay's Letter to the Editor re: Ritter Manuel, Stein Johannes, Barber Neil, et al. WATER III: A Prospective, Partially Randomized Trial of Aquablation Therapy Versus Transurethral Laser Enucleation of the Prostate for Treatment of Lower Urinary Tract Symptoms. Eur Urol Focus 2026;12:266-74.

European urology focus·2026
Same journal

Radioligand Therapy for Prostate Cancer - A Clinical Consultation Guide.

European urology focus·2026
Same journal

Postoperative Pelvic Lymph Node Radiation Therapy in Lymph Node-Positive Prostate Cancer and Mortality Risk.

European urology focus·2026
Same journal

Contemporary Prostate Cancer Intraprostatic Imaging Scores: A Practical and Hands-on Guide for Urologists.

European urology focus·2026
See all related articles

The temporary implantable nitinol device (TIND) offers a minimally invasive option for male lower urinary tract symptoms (LUTS). TIND shows promising medium-term symptom relief and improved urinary flow, with mild side effects.

Area of Science:

  • Urology
  • Minimally Invasive Surgery
  • Medical Devices

Background:

  • Growing interest in minimally invasive (MI) treatments for male lower urinary tract symptoms (LUTS).
  • The temporary implantable nitinol device (TIND) is a novel MI instrument for LUTS.
  • TIND alleviates symptoms by creating prostate incisions via mechanical stress.

Purpose of the Study:

  • To review recent clinical data on the temporary implantable nitinol device (TIND).
  • To evaluate TIND as a minimally invasive procedure for improving male LUTS.

Main Methods:

  • Screened Medline, PubMed, Cochrane Database, and Embase.
  • Included clinical trials, randomized controlled trials, and review articles.
  • Focused on studies of TIND in patients with male LUTS.
Keywords:
Benign prostatic hyperplasiaMale LUTSMinimally-invasive operation

Related Experiment Videos

Main Results:

  • Two studies, including a 36-month follow-up, were available.
  • TIND demonstrated medium-term efficacy: 41% IPSS improvement at 12 months (p<0.001).
  • Maximum urinary flow (Qmax) increased by 4.4ml/s at 12 months (p<0.001); mild complications included UTI and retention.

Conclusions:

  • Preliminary data suggest TIND is a safe and effective MI technique for male LUTS.
  • Symptom relief and improved urinary flow at 36 months are promising.
  • Further long-term results are necessary to fully establish TIND's efficacy.